A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma.

Trial Profile

A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Tandutinib (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 03 May 2013 Planned end date changed from 1 Mar 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 01 May 2012 Planned End Date changed from 1 Jan 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 27 Jun 2011 Planned end date changed to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top